title: [Acute promyelocytic leukemia after living donor partial orthotopic liver transplantation].
abstract: We encountered a 12-year-old girl with acute promyelocytic leukemia (APL) that occurred 21 months after a living donor partial orthotopic liver transplantation from her father for ornithine transcarbamylase deficiency. FK-506 had been administered for prophylaxis against graft-versus-host reaction. The bone marrow specimen revealed a massive infiltration of promyelocytic blasts (M3 by FAB classification) with chromosome 46, XX, t (15; 17) (q22; q12), being the recipient origin. A PML/RAR alpha chimeric gene was detected by RT-PCR. The patient was diagnosed as having APL and successfully induced to complete remission by chemotherapy including daunorubicin (DNR), cytarabine (araC), and all-trans retinoic acid (ATRA). She has been in continuous remission for 12 months after the treatment. Leukemia after liver transplantation is generally taken as a rare complication. However, recent advances in the survival rate of patients who have undergone liver transplantation will lead to an increase of such cases.
authors.affiliation: Department of Pediatrics, School of Medicine, Hokkaido University.
authors.forename: Tomonobu
authors.initials: T
authors.lastname: Sato
authors.forename: Masahide
authors.initials: M
authors.lastname: Nakajima
authors.forename: Akihiro
authors.initials: A
authors.lastname: Iguchi
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D020163:Ornithine Carbamoyltransferase Deficiency Disease / Q000601:surgery*; D012074:Remission Induction; D016559:Tacrolimus / Q000009:adverse effects* / Q000031:analogs & derivatives*; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D007166:Immunosuppressive Agents; D003561:Cytarabine; D014212:Tretinoin; C058028:immunomycin; D016559:Tacrolimus; D003630:Daunorubicin